Customizing Treatment Approaches With High Efficacy Therapies

Author(s):

Ahmed Zayed Obeidat, MD, PhD,Riley Bove, MD

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the definition of high-efficacy therapy and its place in MS care.

EP: 1.Multiple Sclerosis Disease Course and Classification

EP: 2.Defining the Utility of PIRA in Practice

EP: 3.Addressing Inflammation Upon the Diagnosis of MS

EP: 4.Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches

EP: 5.Shared Decision-Making in Multiple Sclerosis Treatment

EP: 6.Clinical Trial Design and Personalized Medicine in Multiple Sclerosis

Now Viewing

EP: 7.Customizing Treatment Approaches With High Efficacy Therapies

EP: 8.When to Stop Multiple Sclerosis Therapy

EP: 9.Immunological Phenotypes of Multiple Sclerosis and Patient Race

EP: 10.Pregnancy and Lactation in Multiple Sclerosis

EP: 11.Bladder Management and Patient-Reported Outcomes in Multiple Sclerosis Management

EP: 12.The Importance of Lifestyle Changes in Multiple Sclerosis Care

EP: 13.Anti-CD20 Therapies for MS

EP: 14.Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies

EP: 15.Safety of Anti-CD20 Therapies in Multiple Sclerosis

EP: 16.Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis

EP: 17.Biomarkers for Dosing Multiple Sclerosis Therapies

EP: 18.Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS

This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.

The conversation revolves around the classification and efficacy of medications used in the treatment of multiple sclerosis (MS). The participants discuss 2 ongoing pragmatic trials: TREAT-MS and DELIVER-MS, which aim to compare different treatment approaches through randomization.

One participant shares their perspective on these trials, emphasizing the importance of objective evidence to support the early aggressive treatment approach in MS. They believe that starting treatment early with more effective therapies can lead to better outcomes, as delaying treatment can result in long-term complications.

In terms of medication efficacy, the participant categorizes medications into high, medium, and traditional efficacy tiers. High-efficacy medications include anti-CD20 therapy, S1P receptor modulators, and cladribine. On the other hand, first-line self-injectable therapies like interferons and glatiramer acetate are considered to be on the lower end of efficacy.

The efficacy of teriflunomide, an oral medication, remains ambiguous. While it was initially considered modestly effective compared to older injectable interferons, recent trial data suggests varying efficacy levels when compared to newer medications like ocrelizumab, ublituximab, and evobrutinib.

There is uncertainty regarding where to place teriflunomide in the current spectrum of MS treatments. Despite its inconsistent efficacy in trials against newer agents, it remains a viable treatment option with potential benefits.

The participants also discuss whether clinical trials are designed to favor teriflunomide. One participant suggests that trials are not intentionally designed to make teriflunomide appear more effective but acknowledges the challenges in determining its exact place in MS treatment protocols.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.